ClinicalTrials.gg
CompletedNCT03312478SHINEUpdated Apr 25, 2022

Association of Type 1 Diabetes Mellitus in Offsprings With Positive Parental History of Diabetes

A Phase 4 interventional study of Blood draw for insulin auto-anti body tests* in Type 1 Diabetes, sponsored by Sanofi. Completed at 1 site in Pakistan. Open to participants aged 2 Years to 20 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-25.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
375
Allocation
Non-randomized
Ages
2 Years to 20 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 67 studies in Diabetes Mellitus, Type 1 by Sanofi — 6 open to participants now, 10 under way, 1 of them phase 3. Diabetes Mellitus, Type 1 · Sanofi.

Enrollment
12th of 60
375 · median 86
Started
2017
with 5 others
Phase 4
14 of 67
none open now
Registered
46th of 67
by date

Among the 67 studies in Diabetes Mellitus, Type 1 by Sanofi, this one is the 12th largest by enrollment of the 60 interventional ones that give a count, is one of 6 that started in 2017, is one of 14 in phase 4, and was the 46th registered.

Diabetes Mellitus, Type 1

3,754 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

6 of the 67 studies in Diabetes Mellitus, Type 1 by Sanofi are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.

This study: 2 Years to 20 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Diabetes Mellitus, Type 1 by Sanofi, or all of them as a file.
02

Study summary

Primary Objective:

To measure the association between a parental history of diabetes and the odds of an offspring being Type 1 diabetics.

Secondary Objectives:

  • To document the profile of Type 1 diabetes patients.
  • To document the glycemic parameters (Fasting blood glucose [FBG] and glycosylated hemoglobin [HbA1c]) of Type 1 diabetes.
  • To capture the current therapeutic management.
Read the detailed description

The overall duration of this study is expected to be 12 months. The recruitment period for a given center will be four months following site initiation of that center. telephonic follow-up for all the patients shall be conducted after 15 days ± 5 days.

*Each patient (cases as well as controls) will be required to undergo laboratory tests for insulin autoantibodies and hemoglobin A1c tests. Both the tests will be conducted through centralized laboratories for all recruited patients.

Since the result of insulin auto-antibodies test is one of the inclusion criteria, it is mandatory for all patients to undergo this test, and detailed information for the same has been included in the informed consent form.

03

Conditions studied

  • Type 1 Diabetes
04

Who can participate

Ages eligible
2 Years to 20 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion criteria :

Inclusion Criteria for Cases

  • Age ≥ 2 years and ≤ 20 years.
  • Type 1 diabetes mellitus (T1DM) at any stage of life assessed as:
  • Insulin initiated within one year of diagnosis.
  • One or more islet autoantibodies (insulin auto-antibodies [IAA], glutamic acid decarboxylase (GAD), or IA2) positive at the time of enrolment. The laboratory value for IAA ≥ 2.4 units/mL, ≥ 10 IU/mL for IA2 and ≥ 5 IU/mL for anti-GAD to be labelled as positive.
  • Consenting to participate in the study or care giver ready to sign data release consent if the patient is less than legal limit which is 18 years of age.

Inclusion Criteria for Controls

  • Age ≥ 2 years and ≤ 20 years. Every control will be matched for a specific patient within ± two years of age.
  • Non diabetic.
  • All islet autoantibodies negative at the time of enrolment (IAA, GAD, or IA2). The laboratory value for IAA ≤ 2.4 units/mL, ≤ 10 IU/mL for IA2, and ≤ 5 IU/mL for anti-GAD to be labelled as negative.
  • Consenting to participate in the study or care giver ready to sign data release consent if the patient is less than 18 years of age.

Exclusion criteria:

Exclusion Criteria for Cases:

  • Age ≤ 2 years and >20 years.
  • Patients with any other pre-existing auto-immune disease.
  • Gestational Diabetes.
  • Pregnant Woman.

Exclusion Criteria for Controls:

  • Age ≤ 2 years and > 20 years.
  • Patient with history of Type 1 (T1) and Type 2 Diabetes Mellitus (T2DM).
  • History of T1 and T2DM in siblings.
  • Gestational Diabetes.
  • Pregnant Woman.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
375 participants (actual)

Study arms

  • Other
    Case

    Known cases of type 1 diabetes mellitus as described in the inclusion criteria for cases

    Drug: Blood draw for insulin auto-anti body tests*

  • Other
    Control

    Age-matched non-diabetic controls as described in the inclusion criteria for controls

    Drug: Blood draw for insulin auto-anti body tests*

Interventions

  • DrugBlood draw for insulin auto-anti body tests*

    Pharmaceutical form: N/A Route of administration: N/A

06

What researchers measure

Primary outcomes

  1. Odds of Type 1 Diabetes Mellitus child having a diabetic parent

    Odds ratio will be used to calculate and measure disease frequency from dichotomous categorical variables

    Time frame: 12 months

Secondary outcomes

  1. Characterization of this population by gender

    Categorical variables (gender) will be presented as proportions

    Time frame: 12 months

  2. Characterization of this population by age

    Categorical variables (age) will be presented as proportions

    Time frame: 12 months

  3. Characterization of this population by socio-economic profile

    Categorical variables (socio-economic profile) will be presented as proportions

    Time frame: 12 months

  4. Means of HbA1c in Type 1 diabetes mellitus (T1DM) patients

    Mean HbA1c

    Time frame: 12 months

  5. Standard deviation of HbA1c in T1DM patients

    Standard deviation of HbA1c

    Time frame: 12 months

  6. Distribution of prescribed therapies by type of insulin to T1DM patients

    Distribution of prescribed therapies by type of insulin will be presented as proportions

    Time frame: 12 months

  7. Means of fasting blood glucose (FBG) in T1DM patients

    Mean Fasting Blood Glucose

    Time frame: 12 months

  8. Standard deviation of FBG in T1DM patients

    Standard deviation of FBG

    Time frame: 12 months

  9. Duration of diabetes in parent

    Mean duration of diabetes in parent

    Time frame: 12 months

  10. Mean duration of diabetes in parent

    Standard deviation of duration of diabetes in parent

    Time frame: 12 months

  11. Characterization of family history of diabetes

    Categorical variables will be measured as proportions

    Time frame: 12 months

  12. Characterization of frequency of consultation

    Number of consultations per month

    Time frame: 12 months

  13. Characterization of diabetes education

    Number of sessions per month

    Time frame: 12 months

07

Study locations

1 site
  • National Institute of Child Health
    Karachi, Sind 75510, Pakistan
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Aug 2018, 10 months.

Of 74 phase 4 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 38. This study's 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2017
First posted
Oct 17, 2017
StartActual
Oct 13, 2017
Primary completionActual
Aug 19, 2018
CompletionActual
Aug 19, 2018
Last update
Apr 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03312478
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Oct 17, 2017
Start date
Oct 13, 2017
Primary completion
Aug 19, 2018
Completion
Aug 19, 2018
Last update
Apr 25, 2022

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion